Water Street Healthcare Partners and JLL Partners have merged their portfolio companies CCBR-SYNARC and BioClinica to create a global provider of specialty outsourced clinical services. CCBR-SYNARC was acquired by Water Street in April 2013 and JLL Partners acquired BioClinica in January 2013.
“This merger creates a market leader uniquely positioned to support pharmaceutical companies with managing key components of their clinical trials,” said Peter Strothman, a Partner at Water Street.
Earlier this year, the two investment firms reached an agreement to merge the two companies and recruited Jeffrey McMullen, an executive with 40 years of experience in the drug development industry, to serve as chairman.
“Together, CCBR-SYNARC and BioClinica offer the industry’s most comprehensive clinical imaging program across all major therapeutic areas that can interact with any contract research organization. In addition, they offer complementary services and software solutions in the high-growth areas of patient recruitment and clinical development,” said Mr. Strothman.
Together, CCBR-SYNARC and BioClinica support pharmaceutical and biotechnology companies with a portfolio of outsourced services that include: medical imaging analysis and consultation that track the effectiveness of new drugs and medical devices across major therapeutic areas, including oncology, neurology, musculoskeletal and cardiology; patient recruitment through a network of 26 dedicated research centers that enroll and retain qualified patients from targeted geographies to participate in trials; software and consulting services that improve the efficiency and management of the drug development process; cardiovascular safety and efficacy that measure the effects of compounds under development on cardiac health, and; central Lab Services that analyze biological samples originating from Phase I-IV trials. BioClinica is based in Newtown, PA (www.bioclinica.com) and CCBR-SYNARC is headquartered in Copenhagen (www.ccbr.com).
“Pharmaceutical and biotechnology companies are increasingly turning to outside specialists to help them manage the cost and complexities of drug development. As one entity, CCBR-SYNARC and BioClinica offer a combination of scientific expertise, clinical trial experience and advanced technologies that solve challenges across the drug development continuum. Their solutions are proven to reduce clinical trial costs, shorten drug development time, and improve data quality and compliance,” said Dan Agroskin, partner, JLL Partners.
JLL Partners seeks to invest in companies across a range of manufacturing and service industries. Sectors of specific interest include healthcare services, medical products, food and consumer products, chemicals, broadcasting, transportation, automotive, industrial manufacturing, and distribution. JLL Partners is based in New York (www.jllpartners.com).
Water Street Healthcare Partners targets investments ranging from $50 million to $500 million in four health care sectors: distribution, medical products, health care services, and pharmaceutical products and services. The firm has particular expertise in corporate divestitures from healthcare companies. Water Street has more than $1 billion of capital under management and is based in Chicago (www.waterstreet.com).
© 2014 PEPD • Private Equity’s Leading News Magazine • 3-12-14